Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Diagnostic accuracy of echocardiography in identifying heart failure related pleural effusions.

Respiratory medicine·2026

Same author

Publisher Correction: Roflumilast.

Nature reviews. Drug discovery·2024

Same author

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023

Same author

CRP (C-Reactive Protein) in Outcome Prediction After Subarachnoid Hemorrhage and the Role of Machine Learning.

Stroke·2021

Same author

Rescue therapy for vasospasm following aneurysmal subarachnoid hemorrhage: a propensity score-matched analysis with machine learning.

Journal of neurosurgery·2021

Same author

Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure.

Clinical genitourinary cancer·2020

Same journal

p38α inhibition restores axonal transport.

Nature reviews. Drug discovery·2026

Same journal

Inflammatory bowel disease-on-a-chip.

Nature reviews. Drug discovery·2026

Same journal

Designing GPCR-targeted miniproteins.

Nature reviews. Drug discovery·2026

Same journal

Pulsatile FXR agonism.

Nature reviews. Drug discovery·2026

Same journal

CRISPR strategy tackles bacterial toxin.

Nature reviews. Drug discovery·2026

Same journal

Time to peak sales: how long is the climb?

Nature reviews. Drug discovery·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 17, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Pazopanib.

Ronald M Bukowski, Uma Yasothan, Peter Kirkpatrick

Nature Reviews. Drug Discovery

|January 1, 2010

Summary

This summary is machine-generated.

Pazopanib, a multikinase inhibitor, was FDA-approved in 2009 for advanced renal cell carcinoma. This targeted therapy inhibits vascular endothelial growth factor receptors, offering a new treatment option.

Related Experiment Videos

Last Updated: Jun 17, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Area of Science:

Oncology
Pharmacology

Background:

The US FDA approved pazopanib (Votrient) in October 2009.
Pazopanib is a multikinase inhibitor targeting vascular endothelial growth factor receptors.

Discussion:

The approval addresses the need for effective treatments for advanced renal cell carcinoma.
Pazopanib represents a targeted therapy approach in cancer treatment.

Key Insights:

Pazopanib's mechanism involves inhibiting key signaling pathways in cancer progression.
The drug targets vascular endothelial growth factor receptors, crucial for tumor angiogenesis.

Outlook:

Further research may explore pazopanib's efficacy in other cancer types.
Continued evaluation of pazopanib's long-term outcomes in renal cell carcinoma is warranted.